Natural Killer (NK)-Cell Lymphoma Market to Expand Significantly by 2032, States DelveInsight Report | Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity

Posted on
by

Natural Killer (NK)-Cell Lymphoma Market to Expand Significantly by 2032, States DelveInsight Report | Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity
The Key Natural Killer (NK)-Cell Lymphoma Companies in the market include – Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity, and others.

 

DelveInsight’s “Natural Killer (NK)-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Natural Killer (NK)-Cell Lymphoma, historical and forecasted epidemiology as well as the Natural Killer (NK)-Cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Natural Killer (NK)-Cell Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Natural Killer (NK)-Cell Lymphoma Market Forecast

 

Some of the key facts of the Natural Killer (NK)-Cell Lymphoma Market Report:

  • The Natural Killer (NK)-Cell Lymphoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • In December 2024, Indapta Therapeutics, Inc., a private clinical-stage biotech firm focused on advanced cell therapies for cancer and autoimmune diseases, announced the closing of a $22.5 million funding round to fast-track the clinical development of its unique allogeneic Natural Killer (NK) cell therapy. The financing was led by existing investors including RA Capital Management, LP, Leaps by Bayer (Bayer AG’s impact investment arm), Vertex Ventures HC, Pontifax, and the Myeloma Investment Fund, the venture philanthropy branch of the Multiple Myeloma Research Foundation.

  • In October 2024, Immunotherapy leader ImmunityBio, Inc. (NASDAQ: IBRX) announced the dosing of the first patients in an initial trial evaluating its CAR-NK cell therapy targeting CD19 for treating non-Hodgkin’s lymphoma (NHL). In the QUILT 106 study, CD19-targeted high-affinity natural killer (t-haNK) cells are initially tested as a single treatment and, after confirming safety, combined with the standard NHL therapy rituximab in patients with selected CD19+ and CD20+ relapsed/refractory B-cell NHL. This Phase 1, open-label trial plans to enroll up to 10 participants and is underway in Johannesburg, Pretoria, and Bloemfontein, South Africa.

  • In October 2024, ImmunityBio announced that the first patients have been treated in an early trial investigating the potential of the company’s CAR-NK cell therapy targeting CD-19 for non-Hodgkin’s lymphoma (NHL).

  • In July 2024, The U.S. Food and Drug Administration (FDA) has approved Nkarta to initiate a clinical trial evaluating its cell therapy candidate NKX019 in patients with ANCA-associated vasculitis (AAV) and other autoimmune diseases.

  • The increased utilization of NK cells in addressing cancer, infections, and liver diseases significantly contributes to the expansion of the market for Natural Killer Cells therapeutics.

  • Key Natural Killer (NK)-Cell Lymphoma Companies: Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity, and others

  • Key Natural Killer (NK)-Cell Lymphoma Therapies: Monalizumab, NKTR-214 (Bempegaldesleukin), ALT 803, ALECSAT, PNK-007, and others

 

Natural Killer (NK)-Cell Lymphoma Overview

Natural Killer (NK)-Cell Lymphoma is a rare and aggressive type of non-Hodgkin lymphoma that arises from natural killer cells, a type of immune cell. It most commonly affects the nasal area and upper respiratory tract but can also spread to other organs. NK-cell lymphoma is often associated with the Epstein-Barr virus (EBV) and is more prevalent in Asian and Latin American populations. Symptoms may include nasal obstruction, bleeding, fever, and weight loss. Due to its aggressive nature, early diagnosis and treatment—typically involving chemotherapy and radiation—are crucial for better outcomes.

 

Request a sample for the Natural Killer (NK)-Cell Lymphoma Market Report:

https://www.delveinsight.com/report-store/natural-killer-nk-cell-lymphoma-market

 

Natural Killer (NK)-Cell Lymphoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Epidemiology Segmentation of Natural Killer (NK)-Cell Lymphoma:

  • Prevalent Cases of Natural Killer (NK)-Cell Lymphoma in the 7MM [2019-2032]

  • Age-Specific Cases of Natural Killer (NK)-Cell Lymphoma in the 7MM [2019–2032]

  • Gender-Specific Cases of Natural Killer (NK)-Cell Lymphoma in the 7MM [2019–2032]

  • Diagnosed and Treated Cases of Natural Killer (NK)-Cell Lymphoma in the 7MM [2019–2032]

 

Download the report to understand which factors are driving Natural Killer (NK)-Cell Lymphoma epidemiology trends @ Natural Killer (NK)-Cell Lymphoma Epidemiology Forecast

 

Natural Killer (NK)-Cell Lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Natural Killer (NK)-Cell Lymphoma market or expected to get launched during the study period. The analysis covers Natural Killer (NK)-Cell Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Natural Killer (NK)-Cell Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Natural Killer (NK)-Cell Lymphoma Pipeline Therapies

  • Monalizumab: Innate Pharma

  • NKTR-214 (Bempegaldesleukin): Nektar Therapeutics

  • ALT 803: ImmunityBio

  • ALECSAT: CytoVac

  • PNK-007: Celularity

 

Discover more about therapies set to grab major Natural Killer (NK)-Cell Lymphoma market share @ Natural Killer (NK)-Cell Lymphoma Medications

 

Scope of the Natural Killer (NK)-Cell Lymphoma Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Natural Killer (NK)-Cell Lymphoma Companies: Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity, and others

  • Key Natural Killer (NK)-Cell Lymphoma Therapies: Monalizumab, NKTR-214 (Bempegaldesleukin), ALT 803, ALECSAT, PNK-007, and others

  • Natural Killer (NK)-Cell Lymphoma Therapeutic Assessment: Natural Killer (NK)-Cell Lymphoma current marketed and Natural Killer (NK)-Cell Lymphoma emerging therapies

  • Natural Killer (NK)-Cell Lymphoma Market Dynamics: Natural Killer (NK)-Cell Lymphoma market drivers and Natural Killer (NK)-Cell Lymphoma market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Natural Killer (NK)-Cell Lymphoma Unmet Needs, KOL’s views, Analyst’s views, Natural Killer (NK)-Cell Lymphoma Market Access and Reimbursement

To know more about Natural Killer (NK)-Cell Lymphoma companies working in the treatment market, visit @ Natural Killer (NK)-Cell Lymphoma Clinical Trials and Therapeutic Assessment

Table of Contents

1. Natural Killer (NK)-Cell Lymphoma Market Report Introduction

2. Executive Summary for Natural Killer (NK)-Cell Lymphoma

3. SWOT analysis of Natural Killer (NK)-Cell Lymphoma

4. Natural Killer (NK)-Cell Lymphoma Patient Share (%) Overview at a Glance

5. Natural Killer (NK)-Cell Lymphoma Market Overview at a Glance

6. Natural Killer (NK)-Cell Lymphoma Disease Background and Overview

7. Natural Killer (NK)-Cell Lymphoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Natural Killer (NK)-Cell Lymphoma

9. Natural Killer (NK)-Cell Lymphoma Current Treatment and Medical Practices

10. Natural Killer (NK)-Cell Lymphoma Unmet Needs

11. Natural Killer (NK)-Cell Lymphoma Emerging Therapies

12. Natural Killer (NK)-Cell Lymphoma Market Outlook

13. Country-Wise Natural Killer (NK)-Cell Lymphoma Market Analysis (2019–2032)

14. Natural Killer (NK)-Cell Lymphoma Market Access and Reimbursement of Therapies

15. Natural Killer (NK)-Cell Lymphoma Market drivers

16. Natural Killer (NK)-Cell Lymphoma Market barriers

17. Natural Killer (NK)-Cell Lymphoma Appendix

18. Natural Killer (NK)-Cell Lymphoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/